DEF: Owlet Seeks Shareholder Vote on Key Governance, Equity, and Warrant Exchange

Owlet, Inc. calls its 2025 Annual Meeting to vote on director elections, an expanded equity plan, officer exculpation, and a major warrant exchange.

Summary

• Owlet, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on Wednesday, October 8, 2025, at 1:00 p.m. (Eastern Time).
• Key proposals include the election of three Class I directors, approval of an amendment to the 2021 Incentive Award Plan to increase shares reserved by 375,000, and ratification of PricewaterhouseCoopers LLP as the independent auditor for 2025.
• Stockholders will also vote on an amendment to the Certificate of Incorporation to provide for officer exculpation from breaches of fiduciary duty, and the approval of the issuance of 5,426,429 shares of Common Stock upon the exchange of outstanding Series A and Series B warrants.
• The warrant exchange involves related parties and aims to simplify the capital structure and reduce dilutive uncertainty, covering approximately 96% of Series A Warrants and all Series B Warrants held by participating holders.
• For the three months ended March 31, 2025, revenues increased by 43.1% to $21,104 thousand, with a net income attributable to common stockholders of $1,748 thousand.
• For the three months ended June 30, 2025, revenues increased by 25.9% to $26,063 thousand, but the company reported a net loss attributable to common stockholders of $(37,187) thousand, largely due to a common stock warrant liability adjustment.
• For the six months ended June 30, 2025, revenues grew by 33.1% to $47,167 thousand, but the net loss attributable to common stockholders was $(35,092) thousand.
• The company continues to report recurring operating losses and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: While the company shows strong revenue growth and improved gross margins, the significant net loss in Q2 2025 (driven by warrant revaluation) and the explicit 'going concern' warning are major concerns. The capital structure simplification is a positive strategic move, but the underlying financial health remains precarious.

Positives

• Revenues increased significantly: 43.1% to $21,104 thousand in Q1 2025 and 25.9% to $26,063 thousand in Q2 2025, driven by higher sales of Dream Sock and Dream Duo products and growth in the Owlet360 subscription service.
• Gross margin improved to 53.7% in Q1 2025 (from 44.4% in Q1 2024) and 51.3% in Q2 2025 (from 49.5% in Q2 2024), attributed to higher revenue, favorable product mix, lower returns, and improved cost absorption.
• The proposed warrant exchange is expected to simplify the company's capital structure, reduce uncertainty regarding potential dilutive effects, and potentially make the Common Stock more attractive to investors.
• The Special Committee successfully negotiated favorable terms for the warrant exchange, including a 60-day volume-weighted average price for stock valuation and a 180-day lockup on newly issued shares.
• The company achieved a net income attributable to common stockholders of $1,748 thousand in Q1 2025, compared to $1,285 thousand in Q1 2024.
• The 'One Big Beautiful Bill Act of 2025' (OBBBA), signed into law on July 4, 2025, reinstates 100% accelerated depreciation and immediate expensing of domestic R&D costs retroactively, which could provide future tax benefits.

Negatives

• The company reported a significant net loss attributable to common stockholders of $(37,187) thousand in Q2 2025, a substantial deterioration from $(2,682) thousand in Q2 2024.
• A large non-cash loss of $(34,753) thousand was recognized in Q2 2025 due to the common stock warrant liability adjustment, reflecting an increase in the fair value of outstanding warrants.
• The company has experienced recurring operating losses and negative cash flows from operations since inception, resulting in an accumulated deficit of $302,817 thousand as of June 30, 2025.
• Net cash used in operating activities increased to $(8,170) thousand for the six months ended June 30, 2025, compared to $(6,721) thousand for the same period in 2024.
• Increased interest expense of $(991) thousand in Q1 2025 and $(979) thousand in Q2 2025, primarily due to new term loan and asset-based revolving credit facilities.
• High customer concentration, with one customer accounting for 64% of net revenues in Q2 2025 and 68% of accounts receivable as of June 30, 2025.
• Litigation settlements totaling $5,250 thousand for securities class action claims and $675 thousand for derivative claims were recognized as general and administrative expenses.

Risks

• The company's recurring operating losses, negative cash flows from operations, and low cash balance raise substantial doubt about its ability to continue as a going concern within one year.
• Failure to generate sufficient future cash flows from operations or obtain additional financing on acceptable terms could materially adversely affect business objectives and financial condition.
• Future issuances of equity or convertible debt securities to raise funds could significantly dilute existing stockholders.
• High dependence on a few large customers creates concentration risk, making the company vulnerable to changes in their purchasing behavior or financial health.
• Ongoing legal proceedings, including class action and derivative complaints, could result in further liabilities, reputational damage, or significant legal expenses.
• Fluctuations in the fair value of common stock warrants, driven by stock price and volatility, can lead to significant non-cash gains or losses, impacting reported net income.
• Failure to comply with reporting and operational covenants under loan facilities could trigger an event of default, leading to forced redemption of outstanding balances.

Future Outlook

The company's future success is dependent on its ability to attract, recruit, motivate, and retain high-quality talent, for which equity-based incentives are considered critical. The proposed amendment to the 2021 Incentive Award Plan aims to facilitate this by allowing for competitive equity awards with longer vesting periods. The warrant exchange is expected to simplify the capital structure, reduce dilutive uncertainty, and improve investor perception, potentially creating greater flexibility for future equity capital raises and strategic transactions. The company is evaluating the potential positive impacts of the 'One Big Beautiful Bill Act of 2025' on its financial statements, particularly regarding accelerated depreciation and R&D expensing. However, the company continues to face substantial doubt about its ability to continue as a going concern and must generate sufficient future cash flows or secure additional financing.

Management Comments

• Kurt Workman, Co-Founder and Chief Executive Officer, expressed inspiration by customers and deep commitment to helping parents find joy and peace of mind through the industry-leading digital health infant monitoring platform.
• On behalf of the Board of Directors and management, appreciation was extended for continued stockholder support, confidence, and investment in Owlet.
• The Board and management believe that equity awards are necessary to remain competitive in the industry and are essential for attracting, recruiting, motivating, and retaining highly qualified employees and other service providers.
• Management advised the Special Committee that engaging in the warrant exchange could improve the company's net income position under GAAP and address certain volatility associated with the Warrants in the company's financial statements.

Industry Context

Owlet operates in the digital health infant monitoring platform industry, a sector where equity compensation is a standard practice for attracting and retaining talent. The company's focus on providing real-time data and insights to parents aligns with broader trends in personalized health and wellness technology. The recent 'One Big Beautiful Bill Act of 2025' (OBBBA) could provide a favorable tax environment for companies investing in R&D and capital expenditures, potentially benefiting Owlet and its industry peers.

Comparison to Industry Standards

• The company's use of equity-based incentives is stated to be consistent with 'market practice' in its competitive industry, indicating alignment with common compensation strategies.
• The company assesses its burn rate (9.3% in 2024, 7.9% three-year average) and equity overhang (18.6% pro forma) as 'reasonable' in light of its trading range and hiring initiatives, suggesting an internal benchmark of acceptable dilution levels.
• No specific comparable companies, projects, or results from competitors or global benchmarks are explicitly mentioned for direct comparison of financial performance or operational efficiency.

Management Changes

Corporate Governance

Legal Proceedings

• Securities Class Actions (Butala v. Owlet, Inc. and Cherian v. Owlet, Inc.): Filed November 2021, alleging violations of the Exchange Act related to FDA classification of Smart Sock. Motions to dismiss denied in August 2024, but reconsideration granted in September 2024 dismissing pre-merger claims. Settlements in principle reached for $3,500 thousand (Section 10(b) Claims) and $1,750 thousand (Section 14(a) Claims), with motions for preliminary approval pending. Trial set for February 17, 2026.
• Derivative Actions (Vargas v. Workman, et al. and Capleton v. Owlet, Inc.): Filed August and October 2024, consolidated in December 2024, asserting Section 14(a) and state law claims. Settlement in principle reached, with a motion for preliminary approval filed April 9, 2025. The company recognized $675 thousand of general and administrative expense for this settlement in Q1 2025.

Related Party Transactions

• 2025 Warrant Exchange: On August 7, 2025, the company entered into an Exchange Agreement with certain warrant holders, including entities affiliated with Eclipse Ventures LLC (Lior Susan, Chairman), Trilogy Equity Partners, LLC (Amy McCullough, Director), John Kim (Director), and Kurt Workman (CEO and Director). These related parties will exchange Series A and Series B Warrants for an aggregate of 5,426,429 newly issued shares of Common Stock.
• February 2024 Private Placement Financing: Issued Series B Preferred Stock and Series B Warrants for $9,250 thousand. Participants included entities affiliated with Eclipse, Trilogy, John Stanton and Theresa Gillespie, and John Kim.
• February 2023 Private Placement Financing: Issued Series A Preferred Stock and Series A Warrants for $30,000 thousand. Participants included entities affiliated with Eclipse, Trilogy, The Melton 2020 Irrevocable Trust, John Stanton and Theresa Gillespie, Samuel Thomsen Trust #2, Peter Thomsen Trust #2, Kurt Workman, and John Kim.
• Amended and Restated Stockholders Agreement: Provides Eclipse with director nomination rights based on its beneficial ownership percentage (currently two directors if >20% voting power, one if >10%). Messrs. Susan and Stoll serve as Eclipse director nominees.

Stakeholder Impact

• Shareholders: Face potential dilution from the expanded equity plan and warrant exchange, but may benefit from a simplified capital structure and improved investor perception. Are impacted by litigation settlements reducing net income and the ongoing 'going concern' uncertainty.
• Employees: Benefit from increased shares available for equity awards, enhancing retention and motivation. Will experience a change in leadership with Jonathan Harris becoming CEO.
• Customers: May benefit from continued investment in research and development, leading to new or improved products. Potential risks if 'going concern' issues impact operations or product availability.
• Creditors (WTI, ABL OPCO LLC): Have loan facilities collateralized by company assets and are subject to covenants. The company's ability to meet financial obligations is tied to its 'going concern' status.
• Officers and Directors: Benefit from proposed officer exculpation, reducing personal liability risk. Involved in related party transactions and subject to corporate governance policies, including the clawback policy.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders virtually on October 8, 2025, to vote on the proposed agenda items.
• If approved, file a Certificate of Amendment to the Certificate of Incorporation with the Delaware Secretary of State to provide for officer exculpation.
• If approved, consummate the warrant exchange, resulting in the issuance of 5,426,429 shares of Common Stock to participating holders.
• Continue to evaluate the impact of the 'One Big Beautiful Bill Act of 2025' on financial statements.
• Monitor the company's ability to generate sufficient future cash flows from operations and/or secure additional financing to address going concern uncertainties.
• Jonathan Harris will succeed Kurt Workman as Chief Executive Officer effective October 1, 2025, with Kurt Workman transitioning to Executive Chairman.

Key Dates

Recommendation

The company exhibits strong revenue growth and improved gross margins, indicating positive operational momentum. However, a significant net loss in Q2 2025, largely due to a non-cash warrant revaluation, and the explicit 'going concern' warning are substantial concerns. The proposed warrant exchange is a strategic move to simplify the capital structure and reduce future dilutive uncertainty, which is positive, but it also involves a considerable issuance of new shares. The upcoming CEO transition adds an element of change. Given the mixed signals of operational strength against severe financial risks and the need to address going concern issues, a 'Hold' recommendation is appropriate. Investors should closely monitor the company's progress in securing additional financing and achieving sustained profitability.

Keywords

Owlet Inc., SEC Filing, Proxy Statement, Annual Meeting, Corporate Governance, Equity Incentive Plan, Warrant Exchange, Officer Exculpation, Financial Results, Q1 2025 Earnings, Q2 2025 Earnings, Going Concern, Capital Structure, Shareholder Vote, NYSE, Digital Health, Infant Monitoring, Financial Performance, Stock Dilution, Litigation, Debt Financing, Revenue Growth, Gross Margin, Net Loss, Cash Flow, Risk Management